デフォルト表紙
市場調査レポート
商品コード
1451768

認知症治療薬市場:適応症別、薬剤クラス別、流通チャネル別、地域別、2024-2032

Dementia Drugs Market by Indication, Drug Class, Distribution Channel, and Region 2024-2032

出版日: | 発行: IMARC | ページ情報: 英文 147 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.96円
認知症治療薬市場:適応症別、薬剤クラス別、流通チャネル別、地域別、2024-2032
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 147 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の認知症治療薬市場は2023年に183億米ドルに達しました。IMARC Groupは、2024年から2032年にかけての成長率(CAGR)は7.09%で、2032年には346億米ドルに達すると予測しています。同市場は、世界人口の高齢化、認知症関連疾患に対する認識と診断の高まり、アルツハイマー病やその他の認知症に対する効果的な治療法を発見するための研究開発の継続などにより、着実な成長を遂げています。

認知症治療薬市場の分析:

市場の成長と規模:世界の認知症治療薬市場は、認知症関連疾患、特にアルツハイマー病の有病率の増加に牽引され、大きな成長を遂げています。世界人口の高齢化と、認知機能低下を管理し患者のQOLを向上させる効果的な治療法に対する需要の高まりにより、市場規模は拡大しています。

技術の進歩:神経画像技術、バイオマーカー同定、精密医療の進歩は、早期診断と個別化された治療計画に役立っています。遠隔医療とデジタルヘルスプラットフォームは、認知症患者と介護者の遠隔モニタリングとサポートを強化しています。

産業用途:認知症治療薬市場は、主にコリンエステラーゼ阻害薬やNMDA受容体拮抗薬などの医薬品に焦点を当てています。認知刺激療法や行動管理戦略などの非薬理学的介入も重要性を増しています。

地理的動向:北米と欧州は認知症の有病率が高く、研究インフラも整っているため、市場が確立しています。アジア太平洋の新興市場は、認知度の向上とヘルスケア投資により急成長を遂げています。

競合情勢:市場は、主要企業が技術革新、合併・買収(M&A)、世界展開に注力する激しい競争を特徴としています。製薬企業も競争力を高めるため、研究開発に多額の投資を行っています。

課題と機会:課題には、医薬品開発の高コスト、規制上のハードル、長期にわたる臨床試験の必要性などがあります。機会は早期診断、新薬の発見、非薬理学的介入にあります。

将来の展望:認知症治療薬市場は、疾患修飾療法と個別化医療に焦点を当て、継続的な成長が見込まれます。神経画像、バイオマーカー同定、遠隔医療などの進歩が認知症ケアの将来を形成すると予想されます。

認知症治療薬の市場動向:

人口の高齢化

認知症治療薬市場の主な促進要因のひとつは、世界人口の高齢化です。人々が長生きするにつれて、認知症のような加齢に関連する疾患の発生率は当然増加します。この人口動態の変化により、認知症関連のヘルスケアサービスや医薬品に対する需要が高まっています。世界保健機関(WHO)の報告によると、60歳以上の人口は2050年までに倍増すると予想されています。このような高齢者人口の増加は、認知症の有病率の急増につながる可能性が高く、それによって効果的な認知症治療薬の需要に拍車をかけています。

技術の進歩

認知症治療薬市場は、医薬品研究開発の著しい進歩によっても牽引されています。認知症の背景にある神経生物学的メカニズムの理解が深まるにつれ、製薬会社はより効果的で的を絞った薬剤の開発にますます投資するようになっています。このような進歩には、最も一般的な認知症であるアルツハイマー病の発症に重要な役割を果たすと考えられているアミロイド斑やタウタンパク質などの新たな治療標的の探索も含まれます。また、陽電子放射断層撮影法(PET)や磁気共鳴画像法(MRI)などの神経画像技術の進歩により、認知症関連疾患のより正確な診断とモニタリングが可能になった。さらに、バイオマーカーの同定や遺伝子研究は、精密医療アプローチの開発を推進しています。創薬、臨床試験デザイン、遠隔医療における技術革新も、認知症治療薬の開発と患者ケアの効率を高めています。

認知度の向上と早期診断

認知症とその症状に対する認識が高まり、早期診断と早期治療につながっています。公衆衛生キャンペーンや教育的イニシアチブは、認知症の初期徴候に対する認識を高め、人々がより早く医師の診断を受けるよう促しています。早期診断は、タイムリーな介入を可能にし、病気の進行を遅らせるため、認知症を効果的に管理する上で極めて重要です。このような意識の高まりと診断技術の向上が、認知症治療薬の需要を牽引しています。

ヘルスケア支出の増加

世界のヘルスケア支出の増加も、認知症治療薬市場を押し上げる要因の一つです。政府およびヘルスケア機関は、認知症を含む慢性疾患の管理および治療に、より多くのリソースを割り当てています。このような資金の増加は、研究、医薬品開発、治療選択肢へのアクセス改善を支援しています。また、ヘルスケアのインフラやサービスを充実させることで、認知症の症状や進行をよりよく管理しようという広範なコミットメントも反映しています。さらに、政府、ヘルスケア団体、擁護団体は、認知症への対応が急務であることを認識しつつあります。このような認識により、研究への資金援助が促進され、医薬品イノベーションを促進する環境が整いつつあります。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 認知症治療薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳:適応症別

  • レビー小体型認知症
    • 市場動向
    • 市場予測
  • パーキンソン病認知症
    • 市場動向
    • 市場予測
  • アルツハイマー病
    • 市場動向
    • 市場予測
  • 血管性認知症
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳:薬剤クラス別

  • コリンエステラーゼ阻害薬
    • 市場動向
    • 市場予測
  • NMDA拮抗薬とその併用薬
    • 市場動向
    • 市場予測

第8章 市場内訳:流通チャネル別

  • 小売薬局
    • 市場動向
    • 市場予測
  • 病院薬局
    • 市場動向
    • 市場予測
  • オンライン薬局
    • 市場動向
    • 市場予測

第9章 市場内訳:地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳:国別
    • 市場予測

第10章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbvie Inc.
    • Apotex Inc.
    • Biogen Inc.
    • Eisai Co. Ltd.
    • Johnson & Johnson
    • Merck & Co. Inc.
図表

List of Figures

  • Figure 1: Global: Dementia Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Dementia Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Dementia Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Dementia Drugs Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Dementia Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 6: Global: Dementia Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Dementia Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Dementia Drugs (Lewy Body Dementia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Dementia Drugs (Lewy Body Dementia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Dementia Drugs (Parkinson's Disease Dementia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Dementia Drugs (Parkinson's Disease Dementia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Dementia Drugs (Alzheimer's Disease) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Dementia Drugs (Alzheimer's Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Dementia Drugs (Vascular Dementia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Dementia Drugs (Vascular Dementia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Dementia Drugs (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Dementia Drugs (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Dementia Drugs (Cholinesterase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Dementia Drugs (Cholinesterase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Dementia Drugs (NMDA Antagonists and its Combination Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Dementia Drugs (NMDA Antagonists and its Combination Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Dementia Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Dementia Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Dementia Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Dementia Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Dementia Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Dementia Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Dementia Drugs Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Dementia Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Dementia Drugs Industry: Value Chain Analysis
  • Figure 79: Global: Dementia Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Dementia Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Dementia Drugs Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 3: Global: Dementia Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 4: Global: Dementia Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Dementia Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Dementia Drugs Market: Competitive Structure
  • Table 7: Global: Dementia Drugs Market: Key Players
目次
Product Code: SR112024A7490

The global dementia drugs market reached US$ 18.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 34.6 Billion by 2032, exhibiting a growth rate (CAGR) of 7.09% during 2024-2032. The market is experiencing steady growth driven by aging global population, increasing awareness and diagnosis of dementia-related conditions, and ongoing research and development efforts to discover effective treatments for Alzheimer's disease and other forms of dementia.

Dementia Drugs Market Analysis:

Market Growth and Size: The global dementia drugs market is experiencing significant growth, driven by the increasing prevalence of dementia-related conditions, particularly Alzheimer's disease. Market size is expanding due to the aging global population and the rising demand for effective treatments to manage cognitive decline and improve the quality of life for patients.

Technological Advancements: Advances in neuroimaging technologies, biomarker identification, and precision medicine are aiding in early diagnosis and personalized treatment plans. Telemedicine and digital health platforms are enhancing remote monitoring and support for dementia patients and caregivers.

Industry Applications: The dementia drugs market is primarily focused on pharmaceuticals, including cholinesterase inhibitors and NMDA receptor antagonists. Non-pharmacological interventions, such as cognitive stimulation therapies and behavioral management strategies, are also gaining importance.

Geographical Trends: North America and Europe have well-established markets due to a higher prevalence of dementia and strong research infrastructure. Emerging markets in Asia-Pacific are experiencing rapid growth due to increasing awareness and healthcare investments.

Competitive Landscape: The market is characterized by intense competition with key players focusing on innovation, mergers and acquisitions (M&A), and expanding their global footprint. Pharmaceutical companies are also investing heavily in research and development to gain a competitive edge.

Challenges and Opportunities: Challenges include the high cost of drug development, regulatory hurdles, and the need for long-term clinical trials. Opportunities lie in early diagnosis, novel drug discovery, and non-pharmacological interventions.

Future Outlook: The dementia drugs market is poised for continued growth with a focus on disease-modifying therapies and personalized medicine. Advances in neuroimaging, biomarker identification, and telemedicine are expected to shape the future of dementia care.

Dementia Drugs Market Trends:

Ageing population

One of the primary drivers of the dementia drugs market is the aging global population. As people live longer, the incidence of age-related diseases like dementia naturally increases. This demographic shift results in a higher demand for dementia-related healthcare services and medications. The World Health Organization reports that the number of people aged 60 years and older is expected to double by 2050. This increase in the elderly population is likely to lead to a surge in the prevalence of dementia, thereby fueling the demand for effective dementia drugs.

Technological Advancements

The dementia drugs market is also driven by significant advancements in pharmaceutical research and development. With a better understanding of the neurobiological mechanisms behind dementia, pharmaceutical companies are increasingly investing in the development of more effective and targeted drugs. These advancements include the exploration of new therapeutic targets, such as amyloid plaques and tau proteins, which are believed to play a crucial role in the development of Alzheimer's disease, the most common form of dementia. Besides, advances in neuroimaging technologies, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), enable more accurate diagnosis and monitoring of dementia-related conditions. Additionally, biomarker identification and genetic research are driving the development of precision medicine approaches. Technological innovations in drug discovery, clinical trial design, and telemedicine are also enhancing the efficiency of dementia drug development and patient care.

Increasing awareness and early diagnosis

There is a growing awareness about dementia and its symptoms, leading to earlier diagnosis and treatment. Public health campaigns and educational initiatives are increasing awareness of dementia's early signs, encouraging people to seek medical advice sooner. Early diagnosis is crucial in managing dementia effectively, as it allows for timely intervention and slows the progression of the disease. This growing awareness, coupled with improvements in diagnostic techniques, is driving the demand for dementia drugs.

Rising healthcare expenditure

Increasing healthcare expenditure globally is another factor boosting the dementia drugs market. Governments and healthcare organizations are allocating more resources to manage and treat chronic conditions, including dementia. This increased funding supports research, drug development, and improved access to treatment options. It also reflects a broader commitment to enhancing healthcare infrastructure and services, thereby facilitating better management of dementia symptoms and progression. Besides, governments, healthcare organizations, and advocacy groups are increasingly recognizing the urgency of addressing dementia. This recognition is driving funding for research and creating an environment conducive to pharmaceutical innovation.

Dementia Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on indication, drug class, and distribution channel.

Breakup by Indication:

Lewy Body Dementia

Parkinson's Disease Dementia

Alzheimer's Disease

Vascular Dementia

Others

Alzheimer's disease accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the dementia drugs market based on the indication. This includes Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease, vascular dementia, and others. According to the report, Alzheimer's disease represented the largest segment.

Breakup by Drug Class:

Cholinesterase Inhibitors

NMDA Antagonists and its Combination Drugs

Cholinesterase inhibitors holds the largest share in the industry

A detailed breakup and analysis of the dementia drugs market based on the drug class has also been provided in the report. This includes cholinesterase inhibitors and NMDA antagonists and its combination drugs. According to the report, cholinesterase inhibitors accounted for the largest market share.

Breakup by Distribution Channel:

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Hospital pharmacies represents the leading market segment

The report has provided a detailed breakup and analysis of the dementia drugs market based on the distribution channel. This includes retail pharmacies, hospital pharmacies, and online pharmacies. According to the report, hospital pharmacies represented the largest segment.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest dementia drugs market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbvie Inc.

Apotex Inc.

Biogen Inc.

Eisai Co. Ltd.

Johnson & Johnson

Merck & Co. Inc.

Key Questions Answered in This Report:

  • How has the global dementia drugs market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global dementia drugs market?
  • What is the impact of each driver, restraint, and opportunity on the global dementia drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive dementia drugs market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the dementia drugs market?
  • What is the breakup of the market based on the drug class?
  • Which is the most attractive drug class in the dementia drugs market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the dementia drugs market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global dementia drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Dementia Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Lewy Body Dementia
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Parkinson's Disease Dementia
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alzheimer's Disease
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Vascular Dementia
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Cholinesterase Inhibitors
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 NMDA Antagonists and its Combination Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Retail Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Hospital Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbvie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Apotex Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Biogen Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eisai Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Johnson & Johnson
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.